About
About Avecho
Board & Leadership
TPM
®
Technology
Portfolio
Pipeline
Phase III Trial
Cannabinoids
Pharmaceutical
Animal Health
Manufacturing
Invest
Investor Centre
Media Centre
Contact
Hit enter to search or ESC to close
Appendix 3X Notices – Three New Directors
April 22, 2015
Click here to read more
Post navigation
Previous Post
Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial
Next Post
Notice of 2015 Annual General Meeting
Related Posts
Phosphagenics Signs Non-Binding Term Sheet for Oxymorphone Patch in Japan
January 31, 2017
2017 Annual Report
March 28, 2018
Avecho’s Phase III Clinical Trial for Insomnia Commences
March 26, 2024
March 26, 2024